20 articles
New research shows brief fasting periods can boost the effectiveness of cancer immunotherapy by reshaping tumor-fighting immune cells.
New fusion model combines hypoxia and immune markers to predict hepatocellular carcinoma treatment success non-invasively.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
New research reveals how the p53 tumor suppressor protein fights cancer by activating cell death pathways when oxygen levels drop.
Review reveals how cardiolipin dysregulation drives glioblastoma survival and identifies potential therapeutic vulnerabilities.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Researchers respond to peer critique of risk-based, non-invasive hepatocellular carcinoma surveillance in metabolic liver disease patients.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
Novel treatment triggers ferroptosis in cancer cells while activating immune responses that further enhance cancer cell death.
Scientists found that inhibiting USP30, a mitochondrial enzyme, restores immune cell function and shrinks tumors in mice.
Tumor cells in intrahepatic cholangiocarcinoma hijack IL-6 signaling to fuel growth — creating a targetable metabolic vulnerability.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
New research identifies HBO1 as a key driver of cancer cell transformation and resistance to CAR-T cell therapy in ovarian cancer.
A new Science paper reveals that mitochondrial fitness in dendritic cells controls antitumor immunity — and can be targeted to boost immunotherapy.
Mechanical tension in the tumor microenvironment controls iron metabolism and cell death susceptibility via a novel NCOA4-FTH1 autophagy axis.
